Data Updates in Transplant Ineligible NDMM

Video

Dr Christina Gasparetto compares the results of the MAIA and SWOG0777 trials and discusses how the data has been practice-changing.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Recent Videos
      Optimizing Maintenance Therapy After First-Line Treatment in HER2+ Metastatic Breast Cancer
      Optimizing Maintenance Therapy After First-Line Treatment in HER2+ Metastatic Breast Cancer
      Current Treatment Approaches in HER2+ Metastatic Breast Cancer
      Current Treatment Approaches in HER2+ Metastatic Breast Cancer
      Complex ES-SCLC Case: Tarlatamab Management Through Toxicity to Clinical Benefit
      Complex ES-SCLC Case: Tarlatamab Management Through Toxicity to Clinical Benefit
      Seamless Transitions: Managing the Inpatient to Outpatient Care Continuum
      Seamless Transitions: Managing the Inpatient to Outpatient Care Continuum
      Future Research Priorities: Optimizing Tarlatamab Administration and Toxicity Management
      Future Research Priorities: Optimizing Tarlatamab Administration and Toxicity Management
      Standardized Toxicity Grading: Institutional Protocols for CRS and ICANS
      Standardized Toxicity Grading: Institutional Protocols for CRS and ICANS
      Differential Toxicity Profile: Tarlatamab vs Traditional Cytotoxic Therapies
      Differential Toxicity Profile: Tarlatamab vs Traditional Cytotoxic Therapies
      The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
      Unique Properties of ISB 2001 May Offer Benefits in R/R Multiple Myeloma
      Nonimmune Adverse Effects: Managing Dysgeusia and Fatigue
      Nonimmune Adverse Effects: Managing Dysgeusia and Fatigue
      CRS Recognition and Intervention: Timing and Clinical Features
      CRS Recognition and Intervention: Timing and Clinical Features
      Related Content
      Mezigdomide with dexamethasone and bortezomib or carfilzomib led to a median PFS exceeding 1 year across 3 cohorts in those with relapsed/refractory MM.

      Mezigdomide Regimens Show Promise in Pretreated R/R Multiple Myeloma

      Tim Cortese
      June 19th 2025
      Article

      Mezigdomide with dexamethasone and bortezomib or carfilzomib led to a median PFS exceeding 1 year across 3 cohorts in those with relapsed/refractory MM.

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

      Samantha Shenoy, NP, MSN
      October 14th 2024
      Podcast

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

      Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

      Ariana Pelosci
      June 16th 2025
      Article

      The MagnetisMM-6 trial showed that elranatamab plus daratumumab and lenalidomide yielded an ORR of 97.3% in transplant-ineligible multiple myeloma.

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

      James R. Berenson, MD, FACP
      September 30th 2024
      Podcast

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Low rates of early relapse in both arms of the phase 3 IsKia trial support the efficacy of carfilzomib in this newly diagnosed multiple myeloma setting.

      Isatuximab Combination Significantly Sustains MRD Negativity in NDMM

      Russ Conroy
      June 16th 2025
      Article

      Low rates of early relapse in both arms of the phase 3 IsKia trial support the efficacy of carfilzomib in this newly diagnosed multiple myeloma setting.

      Quarterly MRD Monitoring After Daratumumab Allows Relapse Detection in Multiple Myeloma

      Quarterly MRD Monitoring After Daratumumab Allows Relapse Detection in Multiple Myeloma

      Ariana Pelosci
      June 14th 2025
      Article

      Results of the PREDATOR-MRD trial found that daratumumab could help predict MRD response for patients with multiple myeloma.